To move Epitalon from experimental to evidence-based, several developments are essential: Randomized, double-blind, placebo-controlled clinical trials, ideally targeting specific endpoints (sleep, immune aging, telomere attrition) Toxicology and long-term safety studies, including exploration of stereoisomer effects and off-target consequences Validated delivery systems (e.g., dendrimer-conjugates, transdermal patches) that make real-world use feasible Pharmacodynamic biomarkers, to identify responders and track efficacy objectively over time Epitalon is not snake oil, but its also not a magic bullet
Recent discoveries shed additional light on the potential role of FAO within specific CD8+ TME subsets
However, insurance may not cover Mounjaro for the purpose of weight loss as it is not approved for weight loss 7
Speake, D., Dvorkin, L., Vaizey, C
ClinicalTrials.gov: NCT05929066 (TRIUMPH-1), NCT05931367 (TRIUMPH-4), NCT06354660 (TRANSCEND-T2D-1)
Gastroenterology 137 , 14671477.e1465 (2009)